Regeneron Pharmaceuticals Stock Rating Upgraded by McLean Capital Management (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at McLean Capital Management from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Friday, American Banking News reports.
A number of other analysts have also recently weighed in on REGN. Analysts at Zacks reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note on Friday. They now have a $344.00 price target on the stock. Separately, analysts at Oppenheimer downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 13th. They now have a $325.00 price target on the stock, up previously from $310.00. They noted that the move was a valuation call. Finally, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $344.00 to $348.00 in a research note on Thursday, February 13th. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $317.91.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 2.25% on Friday, hitting $334.98. 1,535,879 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a one year low of $157.65 and a one year high of $334.83. The stock has a 50-day moving average of $291.4 and a 200-day moving average of $282.1. The company has a market cap of $33.116 billion and a price-to-earnings ratio of 85.99.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 11th. The company reported $2.24 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.97 by $1.27. The company had revenue of $610.00 million for the quarter, compared to the consensus estimate of $579.17 million. During the same quarter in the prior year, the company posted $1.47 earnings per share. The company’s quarterly revenue was up 47.0% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $4.55 EPS for the current fiscal year.
In other Regeneron Pharmaceuticals news, VP Michael Aberman sold 3,648 shares of Regeneron Pharmaceuticals stock on the open market in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $331.42, for a total value of $1,209,020.16. Following the sale, the vice president now directly owns 15,600 shares in the company, valued at approximately $5,170,152. The sale was disclosed in a filing with the SEC, which is available at this link.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.